Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-18 | Cynthia L. Feldmann has served as a director since March 24, 2022... Ms. Feldmann’s qualifications to serve on the Board include her particular knowledge and experience in accounting, finance, and capital markets... 2021 Director Compensation Table shows Cynthia L. Feldmann total compensation of $0. |
| 2023-04-14 | Cynthia L. Feldmann has served as a director since March 24, 2022. Since 2005, Ms. Feldmann has served as a director of STERIS PLC (NYSE: STE), a provider of infection prevention, decontamination, and health science technologies, products, and services, and she currently serves as chair of STERIS’s nominating and governance committee and a member of its audit committee, which she previously chaired. Since 2017, Ms. Feldmann has served as a director of UFP Technologies, Inc. (NYSE: UFPT), a design, engineering, and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, and she currently serves as chair of UFP’s audit committee and a member of its nominating committee. Since 2020, Ms. Feldmann has also served as a director of Frequency Therapeutics, Inc. (NASDAQ: FREQ), a clinical-stage biotechnology company, and she currently serves as the chair of its audit committee. From 2013 until present, Ms. Feldmann has served as a director and, until 2021, as chair of the finance committee of Falmouth Academy, an academically rigorous, co-ed college preparatory day school for grades 7-12. From 2003 to 2018, Ms. Feldmann served as a director of Hanger, Inc. (NYSE: HNGR), a provider of orthotic and prosthetic services and products, and the largest orthotic and prosthetic managed care network in the United States. Ms. Feldmann chaired Hanger’s audit committee and served on its compensation committee and quality and technology committee. Ms. Feldman also previously served as a director of HeartWare International, Inc. (NASDAQ: HeartWare), a medical device company, from 2012 until its acquisition by Medtronic in August 2016. Ms. Feldmann chaired HeartWare’s audit committee and served on its compensation committee and quality and technology committee. From 2012 to 2013, Ms. Feldmann served as a director of Atrius Health, a non-profit organization comprising six leading Boston area physician groups representing more than 1,000 physicians serving nearly 1 million adult and pediatric patients. From 2006 to 2009, Ms. Feldmann served as a director of Hayes Lemmerz International Inc. (NYSE: Hayes), a worldwide producer of aluminum and steel wheels for passenger cars, trucks, and trailers and a supplier of brakes and powertrain components. Ms. Feldmann chaired Hayes’ audit committee. She was the President and Founder of Jetty Lane Associates, a consulting firm, from 2005 until 2012. Ms. Feldmann previously served as Business Development Officer at Edwards Angell Palmer & Dodge LLP, a Boston-based law firm, with a specialty in serving life sciences companies. From 1994 to 2002, she was a Partner at KPMG LLP, holding various leadership roles in the firm’s Medical Technology and Healthcare & Life Sciences industry groups. Ms. Feldmann also served as National Partner-in-Charge of the Life Sciences practice for Coopers & Lybrand (now PricewaterhouseCoopers LLP (PwC)) from 1989 to 1994, among other leadership positions held during her 19-year career with the firm. Ms. Feldmann was a founding board member of MassMEDIC, a Massachusetts trade association for medical technology companies, where she also served as treasurer and board member of the executive committee during her tenure from 1997 to 2001. Ms. Feldmann is a retired CPA and holds a Masters Professional Director Certification from the American College of Corporate Directors. |
| 2024-04-03 | Cynthia L. Feldmann has served as a director since March 2022... The Life Science Committee consists of Directors Freire (Chair), Marcus, Cain, Feldmann, McGrath, and Woronoff. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-28 | Cynthia L. Feldmann 64 Director — 2020, Class III |
| 2018-04-25 | Cynthia L. Feldmann 65 Director 2017 2020, Class III Audit Committee (Chair) Compensation Committee For the fiscal year ended December 31, 2017, non-employee directors received: (i) an annual retainer of $60,000, with a $25,000 cash component and a $35,000 equity component, payable 50% in the form of an unrestricted stock grant and 50% in the form of options, (ii) an annual committee retainer of $5,000 in cash, and an additional $2,500 if the non-employee director served as committee chairman, (iii) reimbursement of expenses for each meeting physically attended, and (iv) an annual lead independent director retainer of $7,500 for the individual serving in that position. Mr. Kozin currently serves as the Lead Independent Director, a position he has held since January 2015. Name Fees Earned or Paid in Cash ($) Stock Awards ($)(1) Option Awards ($)(2)(3) Total ($) Cynthia L. Feldmann 16,250 17,500 17,500 51,250 |
| 2019-04-26 | Cynthia L. Feldmann 66 Director 2017 2020, Class III Audit Committee (Chair) Compensation Committee 32,500 17,500 17,500 67,500 |
| 2020-04-28 | Cynthia L. Feldmann 67 Director 2017 2021 or 2023, Class III Audit Committee X (Chair) Compensation Committee X Ms. Feldmann has served as a director of the Company since June 2017. The Board of Directors has an Audit Committee, which met on seven occasions in 2019, and is currently composed of Messrs. Pierce and Oberdorf and Ms. Feldmann, each of whom meets the enhanced independence standards for audit committee members set forth in applicable SEC rules and Nasdaq listing standards. Ms. Feldmann serves as Chair. Director Compensation—2019 Beginning in June 2019, for the fiscal year ended December 31, 2019, non-employee directors received: (i) an annual retainer of $115,000, with a $45,000 cash component and a $70,000 equity component, payable 50% in the form of restricted stock unit awards (RSU’s) that vest on May 31 of the following year and 50% in the form of stock options that become exercisable on May 31 of the following year, (ii) an annual audit committee retainer of $9,000 in cash, with an additional $11,000 for the non-employee director serving as audit committee chair, (iii) an annual compensation committee retainer of $6,000 in cash, with an additional $9,000 for the non-employee director serving as compensation committee chair, (iv) reimbursement of expenses for each meeting physically attended, and (v) an annual lead independent director retainer of $15,000 for the individual serving in that position. |
| 2021-05-05 | Cynthia L. Feldmann 68 Director 2017 2022 Audit Committee (Chair) Compensation Committee |
| 2022-04-29 | None |
| 2023-04-25 | Cynthia L. Feldmann 70 Director 2017 2024 Audit Committee (Chair) Compensation Committee Director compensation table shows total compensation as $170,000. |
| 2024-04-26 | Cynthia L. Feldmann 71 Director 2017 2025 X (Chair) X |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22